



STABILITY INDICATING RP-HPLC METHOD FOR ESTIMATION OF RABEPRAZOLE SODIUM 




Department of Pharmaceutical Analysis, 
, M. PADMAJA, J. GEETHANJALI, D. VISAGAPERUMAL 
Bapatla College of Pharmacy, Bapatla 522101, Andhra Pradesh, 
Received: 28 Aug 2014 Revised and Accepted: 25 Sep 2014 
India. 
Email: sarachem1981@gmail.com  
ABSTRACT 
Objective: Development and validation of reversed phase liquid chromatographic method for the quantitative determination of Rabeprazole 
sodium and Mosapride citrate in bulk and combined dosage form.  
Methods: A thermo Inert sil, C18 
Results: The retention times of Rabeprazole sodium and Mosapride citrate were 2.951 min and 4.195 min, respectively. Correlation co-efficient for 
Rabeprazole sodium and Mosapride citrate was found to be 0.9999 and 0.9999, respectively. The proposed method was validated with respect to 
linearity, accuracy, precision, specificity, and robustness. Recovery of Rabeprazole sodium and Mosapride citrate in formulations was found to be in 
the range of 97-103 % and 98-102 %, respectively confirms the non-interferences of the excipients in the formulation.  
(250 x 4.6 mm i. d., 5 µ) column with mobile phase containing methanol: buffer (ammonium acetate pH 6.5): 
acetonitrile in the ratio of (50:20:30 %) was used. The flow rate was 1.0 ml/min, column temperature was 25 °C and effluents were monitored at 
245 nm. 
Conclusion: The proposed HPLC method was found to be simple, precise, accurate and sensitive for the simultaneous estimation of Rabeprazole 
sodium and Mosapride citrate in pharmaceutical dosage forms. Due to its simplicity, rapidness and high precision, the method was successfully 
applied to the estimation of Rabeprazole sodium and Mosapride citrate in combined dosage form. 
Keywords: RP-HPLC, Rabeprazole sodium, Mosapride citrate, Methanol, Acetonitrile, Validation. 
 
INTRODUCTION 
Rabeprazole sodium is chemically (RS)-2-[(4-(3-methoxy propaxy)-
3-methylpyridin-2-yl] methyl sulphonyl)-1H-benzo(d)imidazole (fig. 
1). Rabeprazole sodium is an antiulcer drug in the class of proton 
pump inhibitors. As anti ulcer drug, it is used in short-term 
treatment in healing and symptomatic relief of duodenal ulcers and 
erosive or ulcerative gastro esophageal reflux disease (GORD); 
maintaining healing and reducing relapse rates of heartburn 
symptoms in patients with GORD; treatment of daytime and 
nighttime heartburn and other symptoms associated with GORD; 
long-term treatment of pathological hypersecretory conditions, 
including Zollinger-Ellison syndrome and in combination with 










Fig. 1: Chemical structure of Rabeprazole sodium 
 
Mosapride citrate is chemically (RS)-4-amino-5-chloro-2-ethoxy-N-
[(4-(4-fluorobenzyl) morpholin-2-yl)methyl]bezamide citrate (fig. 
2). Mosapride is a gastro pro-kinetic agent that acts as a selective 
5HT4 agonist. The major active metabolite of Mosapride is known as 
M1, additionally acts as a 5HT3
Mosapride also promotes neurogenesis in the gastrointestinal tract 
which may prove useful in certain bowel disorders. The 
neurogenesis is due to Mosapride's effect on the 5-HT
 antagonist. In addition to its pro-
kinetic properties, Mosapride also exerts anti-inflammatory effects 




















where it acts as an agonist [2]. 
 
Fig. 2: Chemical structure of Mosapride citrate 
 
The drug analysis plays an important role in the development of 
drugs, manufacturing and therapeutic use. Pharmaceutical 
industries rely upon quantitative chemical analysis to ensure that 
the raw material used and the final product obtained meets the 
required specification. The literature review indicates there are 
several analytical methods have been reported for estimation of 
these drugs as individual or in combination with other drugs, and 
also several analytical methods for the determination of 
simultaneous estimation of Rabeprazole sodium and Mosapride 
citrate by HPTLC, UPLC and UV in dosage formulation and its bio-
analytical applications. Some of the reported RP-HPLC methods 
were not economical in terms of mobile phase composition, column 
dimensions and run times. Hence there is need for the development 
of newer method for estimation of Rabeprazole sodium and 
Mosapride citrate present in tablet to overcome above discussed 
hurdles. In addition, stability indicating RP-HPLC method for the 
simultaneous estimation of Rabeprazole sodium and Mosapride 
citrate in pharmaceutical dosage form are very scanty. Hence the 
main objective of this study is to develop a stability indicating RP-
HPLC method for estimation of Rabeprazole sodium and Mosapride 
citrate & validate the developed method according to ICH guidelines 
by using various parameters [3-15]. 
MATERIALS AND METHODS 
Chemicals and reagents 
Rabeprazole sodium and Mosapride citrate were obtained as a gift 
sample from Aurobindo Pharma Ltd., Hyderabad. Milli-Q water, 
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HPLC grade methanol, acetonitrile and analytical grade ammonium 
acetate buffer were purchased from E. Merck (India) Ltd., Mumbai. 
Instrumentation 
The separation was carried out on HPLC system with Waters 2695 
alliance with binary HPLC pump, Waters 2998 PDA detector, Waters 
Empower2 software and thermo Inert sil, C18 
HPLC conditions 
(250 x 4.6 mm i. d., 5 µ). 
The mobile phase consisting of methanol, ammonium acetate buffer 
(pH 6.5) and acetonitrile (HPLC grade) were filtered through 0.45 µ 
membrane filter before use, degassed and were pumped from the 
solvent reservoir in the ratio of 50:20:30 % into the column at a flow 
rate of 1.0 ml/min.  
The column temperature was maintained as 25 °C. The detection 
was monitored at 245 nm and the run time was 8 min. The volume 
of injection loop was 10 µl; prior to injection of the drug solution, the 
column was equilibrated for at least 30 min with the mobile phase 
flowing through the system. 
Preparation of standard solution 
20 mg of Rabeprazole sodium and 15 mg of Mosapride citrate were 
accurately weighed and transferred into a 100 ml volumetric flask. 
Dissolved with 25 ml of methanol and sonicated for 20 min.  
Finally, the solution was diluted to the required volume using 
methanol. (200 µg/ml of Mosapride citrate and 150 µg/ml of 
Rabeprazole sodium). From the standard stock solution 2 ml was 
pipetted out into 10 ml volumetric flask and made up the volume 
with mobile phase. (40 µg/ml of Rabeprazole sodium and 30 
µg/ml of Mosapride citrate). 
Preparation of sample solution 
Twenty capsules were accurately weighed and grinded to a fine 
powder. An amount of powder equivalent to 15 mg of Mosapride 
citrate and 20 mg of Rabeprazole sodium were weighed accurately 
and transferred into a 100 ml volumetric flask containing 25 ml of 
methanol and sonicated for 30 min and diluted to 100 ml with 
methanol, then the solution was filtered through 0.45 µm membrane 
filter and 2 ml of filtrate was taken into 10 ml volumetric flask and 
made up to the volume with methanol. 
Procedure 
10 µl of the filtered portion of the sample and standard preparations 
were injected into the chromatograph. The responses for the major 
peaks were recorded and the content of Rabeprazole sodium and 
Mosapride citrate was calculated. 
Validation parameters 
All the analytical validation parameters were determined according 
to ICH guidelines for the proposed analytical method [16-20]. The 
obtained validation parameters are presented in table 2. 
System suitability 
Standard solution was injected six times into system and 
chromatograms were recorded, % RSD (relative standard deviation) 
of retention time & peak area, theoretical plates and tailing factor 
were calculated. 
Accuracy 
Accuracy was determined in terms of % recovery. Sample solutions 
were prepared at three different concentration levels 50 %, 100 % 
and 150 %. Predetermined amount of standard was added to these 
solutions by spiking standard drug solution to the sample. % 
recovery was calculated by assaying these solutions.  
System precision, method precision and intermediate precision 
The system, method and intermediate precision of the proposed 
method are ascertained by injecting 6 replicates of test and standard 
sample, % RSD were calculated.  
Specificity 
Standard solution, sample solution, blank solution and placebo 
solution were injected simultaneously into the system and 
chromatograms were recorded. 
Linearity 
A linear relationship was evaluated across the range of the analytical 
procedure. A series of standard dilutions were prepared from the 
working standard solution in the concentration range of 20-80 
µg/ml of Rabeprazole sodium and 15-60 µg/ml of Mosapride citrate, 
respectively. 10 µl of each solution was injected into HPLC system. 
Linearity is evaluated by plotting the peak area as a function of 
analyte concentrations.  
Robustness 
Robustness was carried out by changing small variations in method 
parameters like flow rate (± 0.2 ml), wavelength (± 2 nm) and 
temperature (± 5° C). Ruggedness wad done by studying changes 
with variation of analyst. 
LOD and LOQ 
The limit of detection (LOD) and limit of quantification (LOQ) were 
determined for Rabeprazole sodium and Mosapride citrate. 
Procedure for forced degradation studies 
In order to demonstrate the stability of both standard and sample 
solutions during analysis, both solutions were analyzed over a 
period of 24 h at room temperature. Further forced degradation 
studies were conducted for indicating the stability of the method 
developed. The results of the degradation studies are presented in 
table 2. 
Acid degradation 
481.6 mg of sample equivalent to 20 mg Rabeprazole sodium & 15 
mg of Mosapride citrate was taken into 100 ml volumetric flask and 
added 10 ml of 0.1N HCl. Then sonicated for 30 min & added 10 ml 
of 0.1N NaOH for neutralisation & diluted volume with methanol. 2 
ml of the above solution was transferred into 10 ml volumetric flask 
& made up volume with methanol in order to get a solution 
containing 40 µg/ml of Rabeprazole sodium & 30 µg/ml Mosapride 
citrate. 
Base degradation 
481.6 mg of sample equivalent to 20 mg of Rabeprazole sodium & 15 
mg of Mosapride citrate was taken into 100 ml volumetric flask & 
added 10 ml of 0.1N NaOH. Then sonicated for 30 min & added 10 
ml of 0.1N HCl for neutralization & diluted volume with methanol. 2 
ml of the above solution was transferred into 10 ml volumetric flask 
& made up volume with methanol in order to get a solution 
containing 40 µg/ml of Rabeprazole sodium & 30 µg/ml Mosapride 
citrate. 
Peroxide degradation 
481.6 mg of sample equivalent to 20 mg Rabeprazole sodium & 15 
mg of Mosapride citrate was taken into 100 ml volumetric flask & 
added 10 ml of 1 % peroxide. Then sonicated for 30 min & diluted 
volume with methanol. 2 ml of the above solution was transferred 
into 10 ml volumetric flask & made up volume with methanol in 
order to get a solution containing 40 µg/ml of Rabeprazole sodium & 
30 µg/ml Mosapride citrate. 
Thermal degradation 
Sample was kept in oven for 1 h at 60 ºC. Above sample 481.6 mg 
equivalent to 20 mg Rabeprazole sodium & 15 mg of Mosapride 
citrate was taken into 100 ml volumetric flask & added 10 ml of 
methanol. Then sonicated for 30 min & diluted volume with 
methanol. 2 ml of the above solution was transferred into 10 ml 
volumetric flask & made up volume with methanol in order to get a 
solution containing 40 µg/ml of Rabeprazole sodium & 30 µg/ml 
Mosapride citrate. 
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UV light degradation 
Sample was kept in sun light for 1 day. Above sample 481.6 mg 
equivalent to 20 mg Rabeprazole sodium & 15 mg of Mosapride 
citrate was taken into 100 ml volumetric flask & added 10 ml of 
methanol. Then sonicated for 30 min & diluted volume with 
methanol. 2 ml of the above solution was transferred into 10 ml 
volumetric flask & made up volume with methanol in order to get a 
solution containing 40 µg/ml of Rabeprazole sodium & 30 µg/ml 
Mosapride citrate. 
RESULTS AND DISCUSSION 
The preliminary studies indicated that the desired system suitability 
parameters were obtained with the mobile phase containing 
methanol: buffer (ammonium acetate pH 6.5): acetonitrile in the 
ratio of (50:20:30 %). The mobile phase eluted the drug at lower 
retention times (2.951 and 4.195 min for Rabeprazole sodium and 
Mosapride citrate, respectively). The corresponding chromatograms 
were shown in the fig. 3 & 4 and the data are presented in table 1. 
 
 




Fig. 4: Sample chromatogram of Rabeprazole sodium and 
Mosapride citrate 
 
Table1: System Suitability Parameters 
Parameters Rabeprazole sodium Mosapride citrate 
Retention time 2.951 4.195 
USP resolution 7.198194 
Theoretical plates 8102.312593 9879.942054 
Tailing 1.127759 1.080256 
The % RSD in precision, accuracy and robustness studies were 
found to be less than 2.0 %, indicating that the method is precise, 
accurate and robust. Accuracy data as shown in table 2. 
 
The retention time of standard and sample solution of Rabeprazole 
sodium and Mosapride citrate were found to be almost same. 
Moreover, the blank solution and placebo solution doesn't produce 
any peak. Hence the proposed analytical method is specific for the 
simultaneous estimation of Rabeprazole sodium and Mosapride 
citrate. The linearity for HPLC method was determined at six 
concentration levels ranging from 20-80 µg/ml for Rabeprazole 
sodium and 15-60 µg/ml for Mosapride citrate. The calibration 
curve was constructed by plotting response factor against respective 
concentration of Rabeprazole sodium and Mosapride citrate.  The 
plots of peak area Vs respective concentration of Rabeprazole sodium 
and Mosapride citrate were found to be linear in the range of 20-80 
µg/ml and 15-60 µg/ml with coefficient of correlation (r2
 
Fig. 5: Linearity curve for Rabeprazole sodium 
 
) 0.9999. The 
linearity of this method was evaluated by linear regression analysis. The 
slope and intercept calculated for Rabeprazole sodium and Mosapride 
citrate were given in fig. 5 and fig. 6. 
 
 
Fig. 6: Linearity curve for Mosapride citrate 
 
Robustness of the method was determined by small deliberate 
changes in flow rate, temperature and wavelength. The low value of 
relative standard deviation indicates that the content of the drug 
was not adversely affected by these changes. Hence, the proposed 
method was robust. The LOD and LOQ were found to be 0.435 µg/ml 
and 1.319 µg/ml for Rabeprazole sodium and 0.594 µg/ml and 1.799 
µg/ml for Mosapride citrate, respectively. The obtained data in 
validation studies are summarized in table 2. From the validation 
study it was cleared that all the observed values were within the 
acceptable range. Therefore, the method attempted to evaluate the 
stability of the drug under various stress conditions with different 
rates of decomposition. The developed method was able to detect 
decomposition. The chromatograms observed from samples, 
subjected to various stress conditions, are shown in fig. 7a to 7e. The 
amount of drug decomposed at various stress conditions are shown 
in table 2. 
 
 
Fig. 7a: Chromatogram of acid degradation 
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Table 2: Validation parameters 
S. 
No. 
Parameter Limits Observation 
Rabeprazole sodium Mosapride citrate 
1 Specificity No interference No interference No interference 
2 System precision  
RSD NMT 2.0 % 
0.32788 0.61058 
Method precision 0.28087 0.79084 











% Recovery range  






Limit of Detection 
Signal noise ratio should be 






Limit of Quantitation 
 
 
Signal noise ratio should be 





7 Asymmetry factor  













Robustness No effect on system suitability 
parameters 
No effect on system suitability 
parameters 
No effect on system suitability 
parameters Change in column temperature, 
Change in flow rate, change in 
wavelength 
10 Degradation % net degradation – 1-50 % - - 
Acid 41.91 % 43.45 % 
Base 34 % 25.79 % 
Peroxide 41.11 % 33.68 % 
Heat 42.89 % 36.50 % 
Sun light 40 % 25.35 % 
 
 
Fig. 7c: Chromatogram of thermal degradation 
 
 
Fig. 7d: Chromatogram of UV degradation 
 
 
Fig. 7e: Chromatogram of base degradation 
CONCLUSION 
The proposed stability indicating RP-HPLC method was found to be 
simple, precise, accurate and sensitive for the simultaneous 
estimation of Rabeprazole sodium and Mosapride citrate in 
pharmaceutical dosage forms. Hence, this method can easily and 
conveniently adopt for routine quality control analysis of 
Rabeprazole sodium and Mosapride citrate in pure and its 
pharmaceutical dosage forms. 
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